News
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
Spatial Imaging of 1,000 RNAs and 100 Proteins Using the CosMx Spatial Molecular Imager Published in Nature Biotechnology
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of its first paper describing the
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Micro Focus International plc
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
Form 8.3 - The Vanguard Group, Inc.: ContourGlobal plc
Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc
Form 8.3 - The Vanguard Group, Inc.: Countryside Partnerships plc
Form 8.3 - The Vanguard Group, Inc.: Capricorn Energy plc
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
EQS-News: EQS Group AG: Repurchase of own shares finished due to closed period
Hardman & Co Research: Arbuthnot Banking Group (ARBB): 3Q’22 trading statement – yet another upgrade
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or
Approval of delisting of Vifor Pharma AG's registered shares
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (SWX:VIFN) (Vifor) announced today that Vifor has received approval for the delisting of the totality of Vifor's
Eutelsat Communications: First Quarter 2022-23 Revenues
Regulatory News:
Eutelsat Communications (ISIN: FR0010221234 - Euronext Paris: ETL) reports revenues for the First Quarter ended 30 September 2022.
In € millions
Q1 2021-22
Q1
Eutelsat Strategy Update on the Proposed Combination with OneWeb
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221011006201/en/
Eutelsat Communications (Euronext Paris: ETL) today
Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
EQS-Adhoc: All for One Group SE resolves on Share Buyback Programme with a volume of up to EUR 5.5 million
